I am a soldier: my battle with cancer Mikhail (Misha) V. Blagosklonny Brief introduction to forthcoming article (or book) On January 12 (my birthday is on January 13) 2023, I was hospitalized to Mass General Hospital in Boston (the most famous hospital in the world) with multiple brain metastasis of lung cancer … Continue Reading
Hyperprogression under immunotherapy and mTOR (hypothesis)
Hyperprogression under immunotherapy and mTOR (hypothesis) Mikhail V. Blagosklonny Abstract: Immunotherapy involving Immune Checkpoint Inhibitors can cause rapid tumor growth, particularly in patients with MDM2 amplification. MDM2 and mTOR inhibitors may mitigate this and improve therapy outcomes. Importantly, MDM2 inhibitors block mTOR in cancer cells. As MDM2 inhibitors aren’t approved for human use, mTOR inhibitors … Continue Reading
I am a soldier: my battle with cancer
I am a soldier: my battle with cancer Mikhail (Misha) V. Blagosklonny Rapamycin is the most effective cancer-preventive drug [1, 2]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103596/ Brief introduction to my forthcoming article (or book) On January 12 (my birthday is on January 13) 2023, I was hospitalized to Mass General Hospital in Boston (the most famous hospital in the … Continue Reading
Doses and schedules of rapamycin for longevity: does aging exist or only age-related diseases?
Doses and schedules of rapamycin for longevity: does aging exist or only age-related diseases? Mikhail Blagosklonny This is a brief version of “groundbreaking paper” that I have no time to finish. Rapamycin for life-limiting disease/condition Current doses and schedules of rapamycin for longevity are based on the wrong objective: to minimize side effects. … Continue Reading
Cancer prevention with rapamycin
Cancer prevention with rapamycin Mikhail V. Blagosklonny Introduction The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In theory, rapamycin (sirolimus) and other rapalogs (temsirolimus, everolimus) may delay cancer by targeting directly pre-cancerous … Continue Reading
Rapamycin for COVID-19 by Mikhail V. Blagosklonny
Section 11 from forthcoming review entitled “From causes of aging to death from COVID-19” (read full review soon) As soon as COVID-19 epidemic started, it become clear that COVID-19 vulnerability is aging-dependent condition and the use of rapamycin (Sirolimus) was immediately suggested by independent researches {Sargiacomo, 2020 #9}, {Zhavoronkov, 2020 #105}, {Zhou, 2020 #94}{Omarjee, 2020 … Continue Reading
How rapamycin prevents muscle loss and sarcopenia (first draft)
The effect of rapamycin, an anti-aging drug, on the muscle, was puzzling for a decade. It seemed paradoxical that rapamycin, an inhibitor of mTOR component 1 (mTORC1), prevents muscle loss and sarcopenia. Yet, this is well established [1-5]. How is that possibly possible? The nutrient-sensing mTOR pathway increases protein synthesis and cellular mass growth. Furthermore, … Continue Reading
Rapamycin: time is now … unless it’s too late
In 2006, I published an article that aging is not caused by free radicals nor by any kind of molecule damage but instead is a quasi-program driven in part by mTOR (Target of Rapamycin). By sheer luck, mTOR inhibitors – Sirolimus (rapamycin) and Everolimus – were clinically available. As I summarized in 2006: “…all diseases of aging … Continue Reading